Pfizer pivots from early-stage rare disease R&D, shifting to external innovation and putting assets up for sale

Pfizer is stepping back from early-stage rare disease R&D. After reviewing its portfolio, the Big Pharma has begun “exploring externalization opportunities for a number of highly innovative, niche programs” as part of a rethink of its approach to orphan indications.